What FreeMind Investments does

FreeMind Investments (FMI) is a Boston-based venture capital fund founded in 2018 as a partnership between FreeMind Group LLC and Daewoong Pharmaceutical Co., Ltd., a South Korean pharmaceutical company. The fund invests in pre-clinical and clinical stage life science companies globally, deploying a proprietary data-driven investment model built on an exclusive database of more than 500 life science companies (covering 2,255 pipeline projects, with ~100 new candidates added annually) and a claimed de-risking formula that combines organizational quality scoring, scientific due diligence by 5,000 key opinion leaders organized in 220 review groups, and business potential assessment. FMI states that over 50% of identified companies exit via IPO or M&A within five years.

The fund's core products are its Exclusive Investments Database and its Proprietary Investment Formula, supported by global offices in Boston, Jerusalem (at Hebrew University's Hi-Tech Center), and Seoul. Its go-to-market is enterprise-style direct investment, with deal flow sourced through the FreeMind Group platform and Daewoong's pharma deal-making networks. FMI monetizes through equity investments and the resulting capital gains upon exits; portfolio companies also receive access to Asian commercial infrastructure, co-development opportunities, and strategic partnerships via Daewoong. The disclosed portfolio spans at least eight companies across induced proximity medicines (General Proximity), GPCR antibody discovery (Abalone Bio), mitophagy small molecules (Vincere Biosciences), oral resolvins for IBD and oncology (Thetis Pharmaceuticals), FDA-cleared digital therapeutics (Renalis Health), nucleic acid diagnostics (Tangen Biosciences), metabolic disease therapeutics (BioKier), and cancer diagnostics (BioMarker Strategies). A notable 2026 transaction was a $20 million investment in General Proximity.

FMI is led by Founder and Managing Partner Ram May-Ron (also Managing Partner of FreeMind Group) and Co-Founder and Venture Partner B. Christopher Kim (former EVP at Bridge Bio and Novartis executive, co-founder of the Korea-Seoul Life Science Fund). Operating geographies span the US, Israel, and South Korea, with 51-100 employees. The legal entity is FreeMind Group LLC, domiciled in Boston, MA, and FreeMind Group is the disclosed parent company.

Name

FreeMind Investments

Legal name

FreeMind Group LLC

Website

https://freemindinvestments.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

FreeMind Investments is a Boston-based venture capital fund, co-founded by FreeMind Group and Daewoong Pharmaceutical, that makes equity investments in pre-clinical and clinical stage life science companies using a proprietary database and de-risking formula, and provides portfolio companies with Asian market access.

Ownership category

akta.pro rank

Product category

Venture Capital (Life Sciences)

NAICS

Portfolio Management and Investment Advice (523940), Other Financial Vehicles (525990), Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Early-Stage Venture Capital (Pre-Seed/Seed) (FSANAAAA)

akta.pro secondary industries

Captive CVC Fund (Dedicated corporate fund structure) (FSANAHAB), Corporate LP Programs (Corporate as LP in VC/PE funds) (FSANAHAH)

Keywords

• Venture capital fund
• Life science investing
• Biotech equity investing
• Pharma deal-making
• Pre-clinical investments

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Investment Returns: FreeMind Investments generates returns through equity investments in life science companies. Returns realized through exits via IPO or M&A. Over 50% of identified companies exit within 5 years.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

FreeMind Investments is a venture capital fund that deploys equity capital into pre-clinical and clinical stage life science companies, selected through a proprietary database of 500+ candidates and a statistically validated de-risking formula. Portfolio companies receive capital plus non-financial benefits including Asian market access, co-development, and pharma deal-making opportunities via co-founding partner Daewoong Pharmaceutical.

Product overview

FreeMind Investments is a venture capital fund that offers a data-driven investment platform for the life science industry, combining a proprietary database of 500+ companies with a statistically validated investment formula. The platform supports the full investment lifecycle from discovery to market, reviewing pre-clinical and clinical stage companies across therapeutics and non-therapeutics. The portfolio includes 10 companies spanning induced proximity medicines (General Proximity), bioactive antibodies (Abalone Bio), mitophagy (Vincere Biosciences), oral resolvins (Thetis Pharmaceuticals), prescription digital therapeutics (Renalis Health), nucleic acid detection (Tangen Biosciences), metabolic surgery-mimicking products (BioKier), and cancer diagnostics (BioMarker Strategies).

Differentiator

Problem solved

Functional benefit

Products and services

• FreeMind Exclusive Investments Database Proprietary database of 500+ life science companies with ~100 new candidates added annually and 4-year rolling data; geographic deal-flow breakdown of US 60% / EU 30% / Israel/Australia/Canada 10%. Total pipeline of 2,255 projects across 568 companies, with 183 top candidate companies used by FMI to source investments.
• FreeMind Proprietary Investment Formula (De-risking Model) Proprietary data-driven investment formula combining organizational quality scores, scientific excellence evaluation, and business potential assessment to identify potential scientific and business success, with a reported 50%+ exit rate (IPO/M&A) within 5 years.
• Equity Investments in Life Science Companies Direct formula-backed equity investments in pre-clinical and clinical stage life science companies across therapeutics and non-therapeutics, paired with non-financial support including pharma deal-making introductions, co-development partnerships, and Asian market access through Daewoong Pharmaceutical.

Quantifiable outcome

• 50%+ of identified companies achieve exit (IPO/M&A) within 5 years

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• FreeMind GroupcoreStrategic or Co-development PartnerCo-founding partner providing proprietary data-driven investment methodology, exclusive database of 500+ life science companies, and scientific due diligence expertise through 5,000+ KOLs.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Atlas Venture: Early-stage biotech-focused venture firm that builds companies around new therapeutics. Directly comparable in stage focus (pre-clinical through clinical) and its data-driven approach to portfolio construction in life sciences.
• Section 32: Venture fund focused on biotech, healthcare, and technology investing, founded by Bill Maris. Comparable to FMI in life sciences stage focus and proprietary thesis-driven approach, though generally larger check sizes.
• OrbiMed: One of the largest dedicated healthcare and life sciences venture capital firms globally, investing across stages from seed to late-stage. Directly comparable to FreeMind Investments in its focus on biotech and life sciences equity investing, though at materially larger fund size.
• ARCH Venture Partners: Early-stage life sciences and technology venture firm that builds companies from inception. Directly comparable to FMI's pre-clinical/clinical focus and hands-on portfolio company formation, though ARCH operates at significantly larger scale.
• RA Capital Management: Boston-based crossover life sciences investor with a strong scientific due diligence orientation and proprietary research platform. Comparable to FMI in its data-driven approach to biotech investing and concentration in clinical-stage assets.
• Flagship Pioneering: Biotech innovation platform that creates and funds breakthrough life sciences companies. Comparable to FMI's pre-clinical focus and proprietary platform approach, though Flagship is significantly larger and more concentrated in company origination.
• Korea-Seoul Life Science Fund: Earlier life sciences fund co-founded by B. Christopher Kim (now a co-founder of FreeMind Investments). Directly comparable by virtue of shared leadership and Asia-US life sciences investment thesis.

Broad incumbents

• Andreessen Horowitz (a16z Bio): Large generalist VC with a dedicated bio/health fund investing across therapeutics and digital health. Comparable in life sciences investing focus but operates as a broader tech VC with bio as one of several verticals.
• Deerfield Management: Large healthcare-focused investment firm investing across public and private life sciences. Comparable in life sciences focus and proprietary research capabilities, though operates across much broader asset classes.

Emerging players

• Cobio Ventures: Life sciences-focused venture fund backing early-stage biotech and medtech. Comparable emerging life science VC with similar stage focus, though smaller scale and less differentiated proprietary infrastructure than FMI.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/freemind-investments

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FreeMind Investments